SMT19969: A Novel Agent For Clostridium Difficile Infection – Summary Results From In Vitro Microbiology And A Randomised Double Blind Phase 1 Clinical Trial
You are leaving Smmttx.com
You have selected a link that will take you to a site maintained by a third party who is solely responsible
for
its contents.
Summit Therapeutics, Inc., is not responsible for the privacy notice of any third-party websites. We encourage you to read the privacy notice of every website you visit.
To stay on Summit’s website, click “Cancel” or click “Continue” to proceed.
SMT19969: A Novel Agent For Clostridium Difficile Infection – Summary Results From In Vitro Microbiology And A Randomised Double Blind Phase 1 Clinical Trial